Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery
/in Colorectal Cancer, Hyperthermia, International PublicationsHyperthermia-enhanced TRAIL- and mapatumumab-induced apoptotic death is mediated through mitochondria in human colon cancer cells
/in Colorectal Cancer, Hyperthermia, International PublicationsImmunotherapy for metastatic colorectal cancer: present status and new options
/in Colorectal Cancer, Dendritic Cells, International PublicationsTumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy
/in Colorectal Cancer, Hyperthermia, International PublicationsLong-term vaccine therapy with autologous whole tumor cell-pulsed dendritic cells for a patient with recurrent rectal carcinoma
/in Colorectal Cancer, Dendritic Cells, International PublicationsInduction of tolerogenic dendritic cells by IL-6-secreting CT26 colon carcinoma
/in Colorectal Cancer, Dendritic Cells, International PublicationsA dendritic cell-based vaccine effects on T-cell responses compared with a viral vector vaccine when administered to patients following resection of colorectal metastases in a randomized phase II study.
/in Colorectal Cancer, Dendritic Cells, International PublicationsSurvival rates among patients vaccinated following resection of colorectal cancer metastases in a phase II randomized study compared with contemporary controls.
/in Colorectal Cancer, Dendritic Cells, International PublicationsImmunogenicity of dendritic cells pulsed with CEA peptide or transfected with CEA mRNA for vaccination of colorectal cancer patients
/in Colorectal Cancer, Dendritic Cells, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer